The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
CX-5461 recently progressed through phase I clinical trial as a first-inhuman inhibitor of RNA-POL I. Here, the authors demonstrate that CX-5461 synergizes with topoisomerase I inhibitors to inhibit neuroblastoma cells and that its primary target in this disease is topoisomerase II beta and not RNA-...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/eab356ebc3d24e3c88297e4fc7fbc176 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:eab356ebc3d24e3c88297e4fc7fbc176 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:eab356ebc3d24e3c88297e4fc7fbc1762021-11-14T12:36:24ZThe chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma10.1038/s41467-021-26640-x2041-1723https://doaj.org/article/eab356ebc3d24e3c88297e4fc7fbc1762021-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-26640-xhttps://doaj.org/toc/2041-1723CX-5461 recently progressed through phase I clinical trial as a first-inhuman inhibitor of RNA-POL I. Here, the authors demonstrate that CX-5461 synergizes with topoisomerase I inhibitors to inhibit neuroblastoma cells and that its primary target in this disease is topoisomerase II beta and not RNA-POL I.Min PanWilliam C. WrightRichard H. ChappleAsif ZubairManbir SandhuJake E. BatchelderBrandt C. HuddleJonathan LowKaley B. BlankenshipYingzhe WangBrittney GordonPayton ArcherSamuel W. BradySivaraman NatarajanMatthew J. PosgaiJohn SchuetzDarcie MillerRavi KalathurSiquan ChenJon Patrick ConnellyM. Madan BabuMichael A. DyerShondra M. Pruett-MillerBurgess B. FreemanTaosheng ChenLucy A. GodleyScott C. BlanchardElizabeth StewartJohn EastonPaul GeeleherNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-20 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Min Pan William C. Wright Richard H. Chapple Asif Zubair Manbir Sandhu Jake E. Batchelder Brandt C. Huddle Jonathan Low Kaley B. Blankenship Yingzhe Wang Brittney Gordon Payton Archer Samuel W. Brady Sivaraman Natarajan Matthew J. Posgai John Schuetz Darcie Miller Ravi Kalathur Siquan Chen Jon Patrick Connelly M. Madan Babu Michael A. Dyer Shondra M. Pruett-Miller Burgess B. Freeman Taosheng Chen Lucy A. Godley Scott C. Blanchard Elizabeth Stewart John Easton Paul Geeleher The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma |
| description |
CX-5461 recently progressed through phase I clinical trial as a first-inhuman inhibitor of RNA-POL I. Here, the authors demonstrate that CX-5461 synergizes with topoisomerase I inhibitors to inhibit neuroblastoma cells and that its primary target in this disease is topoisomerase II beta and not RNA-POL I. |
| format |
article |
| author |
Min Pan William C. Wright Richard H. Chapple Asif Zubair Manbir Sandhu Jake E. Batchelder Brandt C. Huddle Jonathan Low Kaley B. Blankenship Yingzhe Wang Brittney Gordon Payton Archer Samuel W. Brady Sivaraman Natarajan Matthew J. Posgai John Schuetz Darcie Miller Ravi Kalathur Siquan Chen Jon Patrick Connelly M. Madan Babu Michael A. Dyer Shondra M. Pruett-Miller Burgess B. Freeman Taosheng Chen Lucy A. Godley Scott C. Blanchard Elizabeth Stewart John Easton Paul Geeleher |
| author_facet |
Min Pan William C. Wright Richard H. Chapple Asif Zubair Manbir Sandhu Jake E. Batchelder Brandt C. Huddle Jonathan Low Kaley B. Blankenship Yingzhe Wang Brittney Gordon Payton Archer Samuel W. Brady Sivaraman Natarajan Matthew J. Posgai John Schuetz Darcie Miller Ravi Kalathur Siquan Chen Jon Patrick Connelly M. Madan Babu Michael A. Dyer Shondra M. Pruett-Miller Burgess B. Freeman Taosheng Chen Lucy A. Godley Scott C. Blanchard Elizabeth Stewart John Easton Paul Geeleher |
| author_sort |
Min Pan |
| title |
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma |
| title_short |
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma |
| title_full |
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma |
| title_fullStr |
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma |
| title_full_unstemmed |
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma |
| title_sort |
chemotherapeutic cx-5461 primarily targets top2b and exhibits selective activity in high-risk neuroblastoma |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/eab356ebc3d24e3c88297e4fc7fbc176 |
| work_keys_str_mv |
AT minpan thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT williamcwright thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT richardhchapple thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT asifzubair thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT manbirsandhu thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT jakeebatchelder thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT brandtchuddle thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT jonathanlow thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT kaleybblankenship thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT yingzhewang thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT brittneygordon thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT paytonarcher thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT samuelwbrady thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT sivaramannatarajan thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT matthewjposgai thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT johnschuetz thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT darciemiller thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT ravikalathur thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT siquanchen thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT jonpatrickconnelly thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT mmadanbabu thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT michaeladyer thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT shondrampruettmiller thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT burgessbfreeman thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT taoshengchen thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT lucyagodley thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT scottcblanchard thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT elizabethstewart thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT johneaston thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT paulgeeleher thechemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT minpan chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT williamcwright chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT richardhchapple chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT asifzubair chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT manbirsandhu chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT jakeebatchelder chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT brandtchuddle chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT jonathanlow chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT kaleybblankenship chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT yingzhewang chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT brittneygordon chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT paytonarcher chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT samuelwbrady chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT sivaramannatarajan chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT matthewjposgai chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT johnschuetz chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT darciemiller chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT ravikalathur chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT siquanchen chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT jonpatrickconnelly chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT mmadanbabu chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT michaeladyer chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT shondrampruettmiller chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT burgessbfreeman chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT taoshengchen chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT lucyagodley chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT scottcblanchard chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT elizabethstewart chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT johneaston chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma AT paulgeeleher chemotherapeuticcx5461primarilytargetstop2bandexhibitsselectiveactivityinhighriskneuroblastoma |
| _version_ |
1718429141998501888 |